Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2019

01-09-2019 | Metastasis | Clinical

Update on gastric cancer treatments and gene therapies

Authors: Alessio Biagioni, Ileana Skalamera, Sara Peri, Nicola Schiavone, Fabio Cianchi, Elisa Giommoni, Lucia Magnelli, Laura Papucci

Published in: Cancer and Metastasis Reviews | Issue 3/2019

Login to get access

Abstract

Gastric cancer is an active topic of clinical and basic research due to high morbidity and mortality. To date, gastrectomy and chemotherapy are the only therapeutic options for gastric cancer patients, but drug resistance, either acquired or primary, is the main cause for treatment failure. Differences in development and response to cancer treatments have been observed among ethnically diverse GC patient populations. In spite of major incidence, GC Asian patients have a significantly better prognosis and response to treatments than Caucasian ones due to genetic discordances between the two populations. Gene therapy could be an alternative strategy to overcome such issues and especially CRISPR/Cas9 represents one of the most intriguing gene-editing system. Thus, in this review article, we want to provide an update on the currently used therapies for the treatment of advanced GC.
Literature
1.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 68, 394–424. https://​doi.​org/​10.​3322/​caac.​21492.CrossRef
2.
Ishaq, S., & Nunn, L. (2015). Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterology and Hepatology from Bed to Bench, 8(Suppl 1), S6–S14.PubMedPubMedCentral
3.
4.
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Continuous update project report: diet, nutrition, physical activity and stomach cancer 2016. Revised 2018. London: World Cancer Research Fund International; 2018.
5.
6.
7.
Clements, W. M., Wang, J., Sarnaik, A., Kim, O. J., MacDonald, J., Fenoglio-Preiser, C., Groden, J., & Lowy, A. M. (2002). Beta-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Research, 62(12), 3503–3506.PubMed
8.
Feng, R., Chen, X., Yu, Y., Su, L., Yu, B., Li, J., Cai, Q., Yan, M., Liu, B., & Zhu, Z. (2010). miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Letters, 298, 50–63.PubMedCrossRef
9.
10.
11.
12.
13.
14.
15.
16.
17.
Wagner, A. D., Unverzagt, S., Grothe, W., et al. (2010). Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews, 3, CD004064.
18.
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., Kang, Y. K., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687–697.PubMedCrossRef
19.
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H., & Takeuchi, M. (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet Oncology, 9, 215–221.PubMedCrossRef
20.
Ajani, J. A., Buyse, M., Lichinitser, M., et al. (2013). Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer study. Eur J Cancer, 49, 3616–3624.PubMedCrossRef
21.
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010). Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Journal of Clinical Oncology, 28, 1547–1553.PubMedCrossRef
22.
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991–4997.PubMedCrossRef
23.
Al-Batran, S. E., Homann, N., & Pauligk, C. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 393(10184), 1948–1957.PubMedCrossRef
24.
Catalano, V., Graziano, F., Santini, D., D'Emidio, S., Baldelli, A. M., Rossi, D., Vincenzi, B., Giordani, P., Alessandroni, P., Testa, E., Tonini, G., & Catalano, G. (2008). Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? British Journal of Cancer, 99, 1402–1407.PubMedPubMedCentralCrossRef
25.
Hang, Y., Ma, B., Huang, X. T., et al. (2016). Doublet versus single agent as second-line treatment for advanced gastric cancer: a meta-analysis of 10 randomized controlled trials. Medicine, 95, e2792.CrossRef
26.
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., Melichar, B., Tehfe, M., Topuzov, E., Zalcberg, J. R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., Hsu, Y., Liepa, A. M., Gao, L., Schwartz, J. D., & Tabernero, J. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 383, 31–39.PubMedCrossRef
27.
Wilke, H., Muro, K., Van Cutsem, E., et al. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology, 15, 1224–1235.PubMedCrossRef
28.
29.
Thomassen, I., van Gestel, Y. R., van Ramshorst, B., Luyer, M. D., Bosscha, K., Nienhuijs, S. W., Lemmens, V. E., & de Hingh, I. H. (2014). Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. International Journal of Cancer, 134(3), 622–628. https://​doi.​org/​10.​1002/​ijc.​28373.CrossRefPubMed
30.
31.
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K. M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., Ye, X. S., Do, I. G., Liu, S., Gong, L., Fu, J., Jin, J. G., Choi, M. G., Sohn, T. S., Lee, J. H., Bae, J. M., Kim, S. T., Park, S. H., Sohn, I., Jung, S. H., Tan, P., Chen, R., Hardwick, J., Kang, W. K., Ayers, M., Hongyue, D., Reinhard, C., Loboda, A., Kim, S., & Aggarwal, A. (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 21(5), 449–456. https://​doi.​org/​10.​1038/​nm.​3850.CrossRefPubMed
32.
33.
Zhang, J., Huang, J. Y., Chen, Y. N., Yuan, F., Zhang, H., Yan, F. H., Wang, M. J., Wang, G., Su, M., Lu, G., Huang, Y., Dai, H., Ji, J., Zhang, J., Zhang, J. N., Jiang, Y. N., Chen, S. J., Zhu, Z. G., & Yu, Y. Y. (2015). Erratum: whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma. Scientific Reports, 5, 15309. https://​doi.​org/​10.​1038/​srep15309.CrossRefPubMedPubMedCentral
34.
Fang, W. L., Lan, Y. T., Huang, K. H., Liu, C. A., Hung, Y. P., Lin, C. H., Jhang, F. Y., Chang, S. C., Chen, M. H., Chao, Y., Lin, W. C., Lo, S. S., Fen-Yau Li, A., Wu, C. W., Chiou, S. H., & Shyr, Y. M. (2016). Clinical significance of circulating plasma DNA in gastric cancer. International Journal of Cancer, 138(12), 2974–2983. https://​doi.​org/​10.​1002/​ijc.​30018.CrossRefPubMed
35.
Wang, R., Song, S., Harada, K., Ghazanfari Amlashi, F., Badgwell, B., Pizzi, M. P., Xu, Y., Zhao, W., Dong, X., Jin, J., Wang, Y., Scott, A., Ma, L., Huo, L., Vicente, D., Blum Murphy, M., Shanbhag, N., Tatlonghari, G., Thomas, I., Rogers, J., Kobayashi, M., Vykoukal, J., Estrella, J. S., Roy-Chowdhuri, S., Han, G., Zhang, S., Mao, X., Song, X., Zhang, J., Gu, J., Johnson, R. L., Calin, G. A., Peng, G., Lee, J. S., Hanash, S. M., Futreal, A., Wang, Z., Wang, L., & Ajani, J. A. (2019). Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. https://​doi.​org/​10.​1136/​gutjnl-2018-318070.
36.
37.
38.
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians, 55(2), 74–108.
39.
40.
41.
42.
43.
44.
45.
46.
Silva, G., Poirot, L., Galetto, R., Smith, J., Montoya, G., Duchateau, P., & Pâques, F. (2011). Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Current Gene Therapy, 11(1), 11–27 Review.PubMedPubMedCentralCrossRef
47.
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., Dulay, G. P., Hua, K. L., Ankoudinova, I., Cost, G. J., Urnov, F. D., Zhang, H. S., Holmes, M. C., Zhang, L., Gregory, P. D., & Rebar, E. J. (2011). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology, 29(2), 143–148. https://​doi.​org/​10.​1038/​nbt.​1755.CrossRefPubMed
48.
49.
Liang, F., Han, M., Romanienko, P. J., & Jasin, M. (1998). Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 95(9), 5172–5177.PubMedPubMedCentralCrossRef
50.
51.
52.
Haft, D. H., Selengut, J., Mongodin, E. F., & Nelson, K. E. (2005). A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Computational Biology, 1(6), e60.PubMedPubMedCentralCrossRef
53.
54.
55.
Hilton, I. B., D’Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology, 33, 510–517.PubMedPubMedCentralCrossRef
56.
Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., Ter-Ovanesyan, D., Braff, J. L., Davidsohn, N., et al. (2015). Highly efficient Cas9-mediated transcriptional programming. Nature Methods, 12, 326–328.PubMedPubMedCentralCrossRef
57.
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., Guilak, F., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2013). RNA-guided gene activation by CRISPR-Cas9–based transcription factors. Nature Methods, 10, 973–976.PubMedPubMedCentralCrossRef
58.
Sandoval-Bórquez, A., Saavedra, K., Carrasco-Avino, G., Garcia-Bloj, B., Fry, J., Wichmann, I., & Corvalán, A. H. (2015). Noncoding genomics in gastric cancer and the gastric precancerous cascade: pathogenesis and biomarkers. Disease Markers, 2015, 1–14.CrossRef
59.
Bernal, C., Aguayo, F., Villarroel, C., Vargas, M., Díaz, I., Ossandon, F. J., Santibáñez, E., Palma, M., Aravena, E., Barrientos, C., & Corvalan, A. H. (2008). Reprimo as a potential biomarker for early detection in gastric cancer. Clinical Cancer Research, 14, 6264–6269.PubMedCrossRef
60.
61.
Corso, G., Marrelli, D., & Roviello, F. (2012). Familial gastric cancer and germline mutations of E-cadherin. Annali Italiani di Chirurgia, 83(3), 177–182.PubMed
62.
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Schreiber, K. E., Hardwick, R. H., Ausems, M. G., Bardram, L., Benusiglio, P. R., Bisseling, T. M., Blair, V., Bleiker, E., Boussioutas, A., Cats, A., Coit, D., DeGregorio, L., Figueiredo, J., Ford, J. M., Heijkoop, E., Hermens, R., Humar, B., Kaurah, P., Keller, G., Lai, J., Ligtenberg, M. J., O'Donovan, M., Oliveira, C., Pinheiro, H., Ragunath, K., Rasenberg, E., Richardson, S., Roviello, F., Schackert, H., Seruca, R., Taylor, A., Ter Huurne, A., Tischkowitz, M., Joe, S. T., van Dijck, B., van Grieken, N. C., van Hillegersberg, R., van Sandick, J. W., Vehof, R., van Krieken, J. H., & Fitzgerald, R. C. (2015). Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Journal of Medical Genetics, 52(6), 361–374. https://​doi.​org/​10.​1136/​jmedgenet-2015-103094.CrossRefPubMed
63.
64.
Cepko, C., & Pear, W. (2001). Overview of the retrovirus transduction system. Current Protocols in Molecular Biology, 9, 9.9.
65.
Annunziato, S., Kas, S. M., Nethe, M., Yücel, H., Del Bravo, J., Pritchard, C., Bin Ali, R., et al. (2016). Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes & Development, 30(12), 1470–1480.CrossRef
66.
67.
Koizumi, W., Tanabe, S., Saigenji, K., Ohtsu, A., Boku, N., Nagashima, F., Shirao, K., Matsumura, Y., & Gotoh, M. (2003). Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. British Journal of Cancer, 89(12), 2207–2212.PubMedPubMedCentralCrossRef
68.
Ohtsu, Y., Shimada, K., Shirao, N., Boku, I., Hyodo, H., & Saito. (et al.). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). Journal of Clinical Oncology, 21(2003), 54e59.
69.
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991e4997.
70.
71.
Das, K., Chan, X. B., Epstein, D., Teh, B. T., Kim, K. M., Kim, S. T., Park, S. H., Kang, W. K., Rozen, S., Lee, J., & Tan, P. (2016). NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open, 1, e000009.PubMedPubMedCentralCrossRef
72.
Liu, S., Chapman, J. A., Burnell, M. J., Levine, M. N., Pritchard, K. I., Whelan, T. J., Rugo, H. S., Albain, K. S., Perez, E. A., Virk, S., Barry, G., Gao, D., O'Brien, P., Shepherd, L. E., Nielsen TO, & Gelmon, K. A. (2015). Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Research and Treatment, 149(2), 439–448. https://​doi.​org/​10.​1007/​s10549-014-3259-1.CrossRefPubMed
73.
Dulak, A. M., Schumacher, S. E., van Lieshout, J., Imamura, Y., Fox, C., Shim, B., Ramos, A. H., Saksena, G., Baca, S. C., Baselga, J., Tabernero, J., Barretina, J., Enzinger, P. C., Corso, G., Roviello, F., Lin, L., Bandla, S., Luketich, J. D., Pennathur, A., Meyerson, M., Ogino, S., Shivdasani, R. A., Beer, D. G., Godfrey, T. E., Beroukhim, R., & Bass, A. J. (2012). Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Research, 72(17), 4383–4393.PubMedPubMedCentralCrossRef
74.
Lee, J., Sohn, I., Do, I. G., Kim, K. M., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Sohn, T. S., Bae, J. M., Choi, M. G., Lim, D. H., Min, B. H., Lee, J. H., Rhee, P. L., Kim, J. J., Choi, D. I., Tan, I. B., Das, K., Tan, P., Jung, S. H., Kang, W. K., & Kim, S. (2014). Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One, 9, e90133.PubMedPubMedCentralCrossRef
75.
Chen, K., Yang, D., Li, X., et al. (2015). Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 112, 1107e1112.
76.
Busuttil, R. A., Zapparoli, G. V., Haupt, S., et al. (2014). Role of p53 in the progression of gastric cancer. Oncotarget, 5, 12016e12026. 4.CrossRef
77.
Endo, F., Nishizuka, S. S., Kume, K., Ishida, K., Katagiri, H., Ishida, K., Sato, K., Iwaya, T., Koeda, K., & Wakabayashi, G. (2014). A compensatory role of NF-kB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One, 9, e90155.PubMedPubMedCentralCrossRef
78.
79.
80.
Jardim, D. L., de Melo, G. D., Falchook, G. S., Janku, F., Zinner, R., Wheler, J. J., Subbiah, V., Piha-Paul, S. A., Fu, S., Murphy, M. B., Ajani, J., Tang, C., Hess, K., Hamilton, S. R., Roy-Chowdhuri, S., Kurzrock, R., Meric-Bernstam, F., & Hong, D. S. (2014). MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget, 5(7), 1837–1845.PubMedPubMedCentralCrossRef
81.
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery, 7(6), 504–516.PubMedCrossRef
82.
Tuynman, J. B., Lagarde, S. M., Ten Kate, F. J., Richel, D. J., & van Lanschot, J. J. (2008). Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. British Journal of Cancer, 98(6), 1102–1108.PubMedPubMedCentralCrossRef
83.
Lennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., Salgia, R., Bang, Y. J., Clark, J. W., Solomon, B. J., & Iafrate, A. J. (2011). MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology, 29(36), 4803–4810.PubMedPubMedCentralCrossRef
84.
Stahl, M., Maderer, A., Lordick, F., Mihaljevic, A. L., Kanzler, S., Hoehler, T., Thuss-Patience, P., Mönig, S., Kunzmann, V., Schroll, S., Sandermann, A., Tannapfel, A., Meyer, H. J., Schuhmacher, C., Wilke, H., Moehler, M., & Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CAOGI/DGAV) of the German Cancer Society. (2018). Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer, 93, 119–126. https://​doi.​org/​10.​1016/​j.​ejca.​2018.​01.​079.CrossRefPubMed
85.
86.
Cacina, C., Arikan, S., Duzkoylu, Y., Dogan, M. B., Okay, E., Turan, S., et al. (2015). Analyses of EGF A61G gene variation and serum EGF level on gastric cancer susceptibility and clinicopathological parameters. Anticancer Research, 35(5), 2709e13.
87.
Park, D. J., Yoon, C., Thomas, N., Ku, G. Y., Janjigian, Y. Y., Kelsen, D. P., et al. (2014). Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Annals of Surgical Oncology, 21(4), 1130e7.
88.
Takahashi, N., Furuta, K., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., et al. (2016). Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Oncotarget, 7(4), 4925e38.CrossRef
89.
Lim, J. B., Kim, D. K., & Chung, H. W. (2014). Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker. Cancer Science, 105(10), 1327e33.CrossRef
90.
Jang, J. H., Shin, K. H., & Park, J. G. (2001). Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Research, 61, 3541–3543.PubMed
91.
Murase, H., Inokuchi, M., Takagi, Y., et al. (2014). Prognostic significance of the co- overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. Molecular and Clinical Oncology, 2, 509–517.PubMedPubMedCentralCrossRef
92.
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012). Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clinical Cancer Research, 18, 1855–1862.PubMedCrossRef
93.
Van Cutsem, E., Bang, Y. J., Mansoor, W., Petty, R. D., Chao, Y., Cunningham, D., Ferry, D. R., Smith, N. R., Frewer, P., Ratnayake, J., Stockman, P. K., Kilgour, E., & Landers, D. (2017). A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Annals of Oncology, 28(6), 1316–1324. https://​doi.​org/​10.​1093/​annonc/​mdx107.CrossRefPubMed
94.
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Konda, B., & Leichman, L. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of Clinical Oncology, 16, 309–316.PubMedCrossRef
95.
Yamada, Y., Boku, N., Nishina, T., Yamaguchi, K., Denda, T., Tsuji, A., Hamamoto, Y., Konishi, K., Tsuji, Y., Amagai, K., Ohkawa, S., Fujita, Y., Nishisaki, H., Kawai, H., Takashima, A., Mizusawa, J., Nakamura, K., & Ohtsu, A. (2013). Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Annals of Oncology, 24(10), 2560–2565. https://​doi.​org/​10.​1093/​annonc/​mdt238Epub 2013 Jul 24.CrossRefPubMed
96.
97.
Ji, M., Xu, B., Jiang, J. T., Wu, J., Li, X. D., Zhao, W. Q., Zhang, H. Y., Zhou, W. J., & Wu, C. P. (2013). Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer. Onkologie, 36(6), 335–340. https://​doi.​org/​10.​1159/​000351260.CrossRefPubMed
98.
Sato, F., & Meltzer, S. J. (2006). CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer, 106, 483–493.PubMedCrossRef
99.
Kang, C., Song, J. J., Lee, J., & Kim, M. Y. (2014). Epigenetics: an emerging player in gastric cancer. World journal of gastroenterology: WJG, 20, 6433–6447.PubMedCrossRefPubMedCentral
100.
Hamilton, J. P., Sato, F., Jin, Z., Greenwald, B. D., Ito, T., Mori, Y., Paun, B. C., Kan, T., Cheng, Y., Wang, S., Yang, J., Abraham, J. M., & Meltzer, S. J. (2006). Reprimo methylation is a potential biomarker of Barrett’s-associated esophageal neoplastic progression. Clinical Cancer Research, 12, 6637–6642.PubMedCrossRef
101.
Eads, C. A., Lord, R. V., Wickramasinghe, K., Long, T. I., Kurumboor, S. K., Bernstein, L., Peters, J. H., DeMeester, S., DeMeester, T., Skinner, K. A., & Laird, P. W. (2001). Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Research, 61, 3410–3418.PubMed
102.
Wang, J. S., Guo, M., Montgomery, E. A., Thompson, R. E., Cosby, H., Hicks, L., Wang, S., Herman, J. G., & Canto, M. I. (2009). DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus. The American Journal of Gastroenterology, 104, 2153–2160.PubMedPubMedCentralCrossRef
103.
Oka, D., Yamashita, S., Tomioka, T., Nakanishi, Y., Kato, H., Kaminishi, M., & Ushijima, T. (2009). The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer, 115, 3412–3426.PubMedCrossRef
104.
Schneider, B. J., Shah, M. A., Klute, K., Ocean, A., Popa, E., Altorki, N., Lieberman, M., Schreiner, A., Yantiss, R., Christos, P. J., Palmer, R., You, D., Viale, A., Kermani, P., & Scandura, J. M. (2017). Phase I Study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of tumor hypomethylation as an indicator of major histopathologic response. Clinical Cancer Research, 23(11), 2673–2680. https://​doi.​org/​10.​1158/​1078-0432.​CCR-16-1896.CrossRefPubMed
105.
Marin, J. J., Al-Abdulla, R., Lozano, E., Briz, O., Bujanda, L., Banales, J. M., & Macias, R. I. (2016). Mechanisms of resistance to chemotherapy in gastric cancer. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 318–334 Review.PubMedCrossRef
106.
Khare, P. D., Shao-Xi, L., Kuroki, M., Hirose, Y., Arakawa, F., Nakamura, K., Tomita, Y., & Kuroki, M. (2001). Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Research, 61(1), 370–375.PubMed
107.
Shaw, D. M., Embleton, M. J., Westwater, C., Ryan, M. G., Myers, K. A., Kingsman, S. M., Carroll, M. W., & Stern, P. L. (2000). Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4. Biochimica et Biophysica Acta, 1524(2–3), 238–246.PubMedCrossRef
108.
109.
Ohashi, M., Kanai, F., Ueno, H., Tanaka, T., Tateishi, K., Kawakami, T., Koike, Y., Ikenoue, T., Shiratori, Y., Hamada, H., & Omata, M. (1999). Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut, 44(3), 366–371.PubMedPubMedCentralCrossRef
110.
Okino, T., Onda, M., Matsukura, N., Inada, K. I., Tatematsu, M., Suzuki, S., & Shimada, T. (2001). Sequential histopathological changes in vivo after suicide gene therapy of gastric cancer induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. Japanese Journal of Cancer Research, 92(6), 673–679.PubMedCrossRefPubMedCentral
111.
Shimizu, T., Shimada, H., Ochiai, T., & Hamada, H. (2001). Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl transferase and herpes simplex virus thymidine kinase). Cancer Gene Therapy, 8, 512–521.PubMedCrossRef
112.
Metadata
Title
Update on gastric cancer treatments and gene therapies
Authors
Alessio Biagioni
Ileana Skalamera
Sara Peri
Nicola Schiavone
Fabio Cianchi
Elisa Giommoni
Lucia Magnelli
Laura Papucci
Publication date
01-09-2019
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2019
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-019-09803-7

Other articles of this Issue 3/2019

Cancer and Metastasis Reviews 3/2019 Go to the issue

ReviewPaper

The role of proteases in epithelial-to-mesenchymal cell transitions in cancer

Clinical

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

ReviewPaper

Differential roles of protease isoforms in the tumor microenvironment

ReviewPaper

Role of meprin metalloproteases in metastasis and tumor microenvironment

Announcement

Biography—Judith Clements

ReviewPaper

KISS1 in breast cancer progression and autophagy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits